MX2017002476A - Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular. - Google Patents
Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular.Info
- Publication number
- MX2017002476A MX2017002476A MX2017002476A MX2017002476A MX2017002476A MX 2017002476 A MX2017002476 A MX 2017002476A MX 2017002476 A MX2017002476 A MX 2017002476A MX 2017002476 A MX2017002476 A MX 2017002476A MX 2017002476 A MX2017002476 A MX 2017002476A
- Authority
- MX
- Mexico
- Prior art keywords
- airway
- methods
- extracellular matrix
- fibroblast proliferation
- matrix deposition
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 title abstract 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 title abstract 2
- 230000001594 aberrant effect Effects 0.000 title abstract 2
- 230000008021 deposition Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 210000002744 extracellular matrix Anatomy 0.000 title abstract 2
- 210000002950 fibroblast Anatomy 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000035755 proliferation Effects 0.000 title abstract 2
- 208000000884 Airway Obstruction Diseases 0.000 abstract 2
- 208000036065 Airway Remodeling Diseases 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 208000037273 Pathologic Processes Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 230000009054 pathological process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Marine Sciences & Fisheries (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/473,339 US9890200B2 (en) | 2011-04-12 | 2014-08-29 | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| PCT/US2015/047390 WO2016033432A1 (en) | 2014-08-29 | 2015-08-28 | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017002476A true MX2017002476A (es) | 2017-08-14 |
Family
ID=52583553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017002476A MX2017002476A (es) | 2014-08-29 | 2015-08-28 | Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9890200B2 (enExample) |
| EP (1) | EP3185883A4 (enExample) |
| JP (1) | JP2017528454A (enExample) |
| KR (1) | KR20170044171A (enExample) |
| CN (1) | CN107073075A (enExample) |
| AU (1) | AU2015308761A1 (enExample) |
| BR (1) | BR112017003731A2 (enExample) |
| CA (1) | CA2958085A1 (enExample) |
| MX (1) | MX2017002476A (enExample) |
| RU (1) | RU2017110093A (enExample) |
| SG (1) | SG11201701135WA (enExample) |
| WO (1) | WO2016033432A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9890200B2 (en) | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| US10087225B2 (en) | 2015-01-08 | 2018-10-02 | Moerae Matrix, Inc. | Formulation of MK2 inhibitor peptides |
| RU2017135072A (ru) * | 2015-03-12 | 2019-04-10 | Мори Матрикс, Инк. | Применение пептидсодержащих композиций ингибитора mk2 для лечения немелкоклеточного рака легкого |
| CN112920256B (zh) * | 2019-11-21 | 2022-08-19 | 上海医药工业研究院 | 一种治疗哮喘的生物肽及其应用 |
| WO2023134764A1 (zh) | 2022-01-14 | 2023-07-20 | 上海翰森生物医药科技有限公司 | 含吡啶多环类衍生物、其制备方法和应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1521000A (en) | 1975-06-13 | 1978-08-09 | Syntex Puerto Rico Inc | Inhalation device |
| US4227522A (en) | 1978-09-05 | 1980-10-14 | Syntex Puerto Rico, Inc. | Inhalation device |
| US4192309A (en) | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| NL192564C (nl) | 1982-10-08 | 1997-10-03 | Glaxo Group Ltd | Inrichting voor het toedienen van medicamenten aan patiënten. |
| EP0211595B1 (en) | 1985-07-30 | 1991-11-13 | Glaxo Group Limited | Devices for administering medicaments to patients |
| JPH05963A (ja) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
| US6331318B1 (en) | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
| US5352461A (en) | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
| AU4115693A (en) | 1992-04-24 | 1993-11-29 | Sri International | In vivo homologous sequence targeting in eukaryotic cells |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| CN1048254C (zh) | 1993-12-09 | 2000-01-12 | 托马斯杰弗逊大学 | 用于将预定的改变引入靶基因中的化合物 |
| JPH09510191A (ja) * | 1994-02-17 | 1997-10-14 | アメリカン・ホーム・プロダクツ・コーポレイション | ホスホジエステラーゼ阻害薬としての置換ビフェニル誘導体 |
| US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
| CA2367131C (en) | 1999-04-05 | 2007-07-03 | Solomon S. Steiner | Methods for fine powder formation |
| EP2280004B1 (en) | 1999-06-29 | 2016-04-20 | MannKind Corporation | Pharmaceutical formulations comprising insulin complexed with a diketopiperazine |
| MXPA04010560A (es) | 2002-04-25 | 2005-08-15 | Scripps Research Inst | Tratamiento y prevencion de condiciones pulmonares. |
| PL218992B1 (pl) | 2002-07-19 | 2015-02-27 | Abbott Biotech Ltd | Neutralizujące o wysokim powinowactwie izolowane ludzkie przeciwciało anty-TNFα, zastosowanie tego przeciwciała, kryształ zawierający ludzkie przeciwciało anty-TNFα i preparat zawierający ten kryształ |
| JP2007537296A (ja) | 2004-05-14 | 2007-12-20 | アボット・ラボラトリーズ | 治療薬としてのキナーゼ阻害薬 |
| DK1786784T3 (da) | 2004-08-20 | 2011-02-14 | Mannkind Corp | Katalyse af diketopiperazinsyntese |
| KR20070057829A (ko) | 2004-08-23 | 2007-06-07 | 맨카인드 코포레이션 | 포스포디에스테라아제 5형의 억제제의 폐 전달 |
| CN104436170B (zh) | 2004-08-23 | 2018-02-23 | 曼金德公司 | 用于药物输送的二酮哌嗪盐 |
| AU2006290227B2 (en) | 2005-09-14 | 2012-08-02 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
| KR20080096809A (ko) | 2006-02-22 | 2008-11-03 | 맨카인드 코포레이션 | 디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법 |
| TW200817047A (en) * | 2006-04-03 | 2008-04-16 | Teva Pharma | Drug microparticles |
| DK2155228T3 (da) * | 2007-01-10 | 2014-07-07 | Purdue Research Foundation | Polypeptidinhibitorer af HSP27-kinase og anvendelser herfor |
| US8063094B2 (en) | 2007-02-08 | 2011-11-22 | Boehringer Ingelheim International Gmbh | Anti-cytokine heterocyclic compounds |
| US20080282320A1 (en) | 2007-05-11 | 2008-11-13 | Denovo Andrew | Security Compliance Methodology and Tool |
| JP5703466B2 (ja) | 2007-08-07 | 2015-04-22 | パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | キナーゼ阻害薬およびその使用 |
| KR20170001756A (ko) | 2008-10-20 | 2017-01-04 | 모레 매트릭스 인코포레이티드 | 유착 치료 또는 예방용 폴리펩티드 |
| AU2009324661A1 (en) | 2008-12-10 | 2011-07-07 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
| AU2013202108B2 (en) * | 2008-12-10 | 2015-12-24 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
| US20130115256A1 (en) | 2010-05-24 | 2013-05-09 | Cynthia Lander | Methods for treating or preventing vascular graft failure |
| US9890200B2 (en) | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| SG194135A1 (en) | 2011-04-12 | 2013-11-29 | Matrix Inc Moerae | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
-
2014
- 2014-08-29 US US14/473,339 patent/US9890200B2/en not_active Expired - Fee Related
-
2015
- 2015-08-28 RU RU2017110093A patent/RU2017110093A/ru not_active Application Discontinuation
- 2015-08-28 CA CA2958085A patent/CA2958085A1/en not_active Abandoned
- 2015-08-28 MX MX2017002476A patent/MX2017002476A/es unknown
- 2015-08-28 CN CN201580058532.3A patent/CN107073075A/zh active Pending
- 2015-08-28 WO PCT/US2015/047390 patent/WO2016033432A1/en not_active Ceased
- 2015-08-28 AU AU2015308761A patent/AU2015308761A1/en not_active Abandoned
- 2015-08-28 SG SG11201701135WA patent/SG11201701135WA/en unknown
- 2015-08-28 KR KR1020177007622A patent/KR20170044171A/ko not_active Withdrawn
- 2015-08-28 EP EP15835631.1A patent/EP3185883A4/en not_active Withdrawn
- 2015-08-28 BR BR112017003731A patent/BR112017003731A2/pt not_active IP Right Cessation
- 2015-08-28 JP JP2017511933A patent/JP2017528454A/ja active Pending
-
2017
- 2017-12-27 US US15/855,398 patent/US10562947B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2958085A1 (en) | 2016-03-03 |
| JP2017528454A (ja) | 2017-09-28 |
| RU2017110093A3 (enExample) | 2018-10-01 |
| KR20170044171A (ko) | 2017-04-24 |
| US20180194817A1 (en) | 2018-07-12 |
| US9890200B2 (en) | 2018-02-13 |
| AU2015308761A1 (en) | 2017-02-23 |
| WO2016033432A9 (en) | 2016-04-21 |
| US10562947B2 (en) | 2020-02-18 |
| US20150064134A1 (en) | 2015-03-05 |
| CN107073075A (zh) | 2017-08-18 |
| WO2016033432A1 (en) | 2016-03-03 |
| RU2017110093A (ru) | 2018-10-01 |
| EP3185883A4 (en) | 2018-05-30 |
| EP3185883A1 (en) | 2017-07-05 |
| BR112017003731A2 (pt) | 2017-12-05 |
| SG11201701135WA (en) | 2017-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX359516B (es) | Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular. | |
| MX2017006372A (es) | Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matrix extracelular. | |
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| MX2021002321A (es) | Nuevos metodos. | |
| PH12019501215A1 (en) | Conjugates comprising an glp-1/glucagon dual agonist, a linker and hyaluronic acid | |
| PH12019501985A1 (en) | Fused imidazo-piperidine jak inhibitors | |
| AU2016293674B2 (en) | A novel approach for treatment of cancer using immunomodulation | |
| NZ600544A (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
| WO2017009843A3 (en) | Compositions, articles of manufacture and methods for treating cancer | |
| EA033113B1 (ru) | Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта | |
| MX340015B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| WO2016033432A9 (en) | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition | |
| MX2025009723A (es) | Metodos de tratamiento contra adicciones | |
| PH12017502087A1 (en) | Tiotropium inhalation solution for nebulization | |
| PH12014500674A1 (en) | Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments | |
| MX2021011269A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina. | |
| CR20230177A (es) | Compuestos y composiciones como moduladores de señalización tlr | |
| PH12021552358A1 (en) | Compounds and compositions as modulators of tlr signaling | |
| MX2019006942A (es) | Agonistas de receptores de oxitocina no peptidicos. | |
| EP4400119A3 (en) | Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (bos) | |
| MY193963A (en) | Composition for treating joint diseases and kit containing same | |
| NZ744942A (en) | Compositions and methods for treating nasal and paranasal mucosa diseases with nicotinic acetylcholine receptor agonists | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| PH12019500841A1 (en) | Nebulized tiotropium | |
| EP4620940A3 (en) | Synthesis of (+)-cannabinoids and their therapeutic effects |